Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4896MR)

This product GTTS-WQ4896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4896MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1607MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ7867MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ14179MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ11442MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ4901MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ11727MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ4362MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ2677MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW